<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04093596</url>
  </required_header>
  <id_info>
    <org_study_id>ALLO-715-101</org_study_id>
    <nct_id>NCT04093596</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)</brief_title>
  <acronym>UNIVERSAL</acronym>
  <official_title>A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy With or Without Nirogacestat in Subjects With Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allogene Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allogene Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the UNIVERSAL study is to assess the safety, efficacy, cell kinetics, and&#xD;
      immunogenicity of ALLO-715 with or without Nirogacestat in adults with relapsed or refractory&#xD;
      multiple myeloma after a lymphodepletion regimen of ALLO-647 in combination with fludarabine&#xD;
      and/or cyclophosphamide, or ALLO-647 alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 23, 2019</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-715</measure>
    <time_frame>28 Days</time_frame>
    <description>Dose limiting toxicities are defined as ALLO-715-related adverse events with onset within 28 days following infusion of ALLO-715.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the overall safety profile and tolerability of ALLO-647 in combination with Fludarabine and/or cyclophosphamide or ALLO-647 alone, prior to ALLO-715 to confirm the dose of ALLO-647.</measure>
    <time_frame>33 days</time_frame>
    <description>The proportion of subjects in a dose cohort with DLTs of ALLO-647</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the overall safety profile and tolerability of nirogacestat given concomitantly with ALLO-715 following lymphodepletion with Flu/ Cy/ ALLO-647.</measure>
    <time_frame>28 days</time_frame>
    <description>Dose limiting toxicities are defined as ALLO-715-related adverse events with onset within 28 days following infusion of ALLO-715.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cellular kinetics of ALLO-715</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Levels of anti-BCMA CAR T cells in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>antitumor activity of ALLO-715 in combination with nirogacestat</measure>
    <time_frame>up to 36 months</time_frame>
    <description>overall -response rate (ORR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular kinetics of ALLO-715 in combination with nirogacestat</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Levels of anti-BCMA CAR T cells in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ALLO-647</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Serum concentration levels of ALLO-647</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of nirogacestat</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Serum concentration levels of nirogacestat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of immunogenicity against ALLO-715 and ALLO-647</measure>
    <time_frame>up to 36 months</time_frame>
    <description>detection and levels of anti-drug antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune monitoring after lymphodepletion regimen</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Detection of the following circulating cells: T cell subset, B lymphocytes, and NK cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of ALLO-715</measure>
    <time_frame>up to 36 months</time_frame>
    <description>overall response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of ALLO-715</measure>
    <time_frame>up to 36 months</time_frame>
    <description>duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of ALLO-715</measure>
    <time_frame>up to 36 months</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of ALLO-715</measure>
    <time_frame>up to 36 months</time_frame>
    <description>minimal residual disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the expression of BCMA in bone marrow plasma cells with and without nirogacestat</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Overall response rate of ALLO-715 with and without Nirogacestat</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Relapsed/Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>ALLO-647, ALLO-715, Nirogacestat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ALLO-715</intervention_name>
    <description>ALLO-715 is an allogeneic CAR T cell therapy targeting BCMA</description>
    <arm_group_label>ALLO-647, ALLO-715, Nirogacestat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALLO-647</intervention_name>
    <description>ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen</description>
    <arm_group_label>ALLO-647, ALLO-715, Nirogacestat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Chemotherapy for lymphodepletion</description>
    <arm_group_label>ALLO-647, ALLO-715, Nirogacestat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Chemotherapy for lymphodepletion</description>
    <arm_group_label>ALLO-647, ALLO-715, Nirogacestat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nirogacestat</intervention_name>
    <description>a small molecule, selective, reversible, noncompetitive inhibitor of Î³secretase (GSI) that increases BCMA target density on the surface of multiple myeloma cells.</description>
    <arm_group_label>ALLO-647, ALLO-715, Nirogacestat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented diagnosis of relapsed/refractory multiple myeloma (MM) with measurable&#xD;
             disease (serum, urine, or free light chain [FLC]) per International Myeloma Working&#xD;
             Group (IMWG) criteria&#xD;
&#xD;
          -  At least 3 prior lines of MM therapy, including a proteasome inhibitor,&#xD;
             immunomodulatory agent, and anti-CD38 antibody (unless contraindicated), and&#xD;
             refractory to the last treatment line.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0 or 1&#xD;
&#xD;
          -  Absence of donor (product)-specific anti-HLA antibodies&#xD;
&#xD;
          -  Adequate hematologic, renal, hepatic, pulmonary, and cardiac function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or history of Central Nervous System (CNS) involvement of myeloma or plasma&#xD;
             cell leukemia&#xD;
&#xD;
          -  Clinically significant CNS disorder&#xD;
&#xD;
          -  Current or history of thyroid disorder&#xD;
&#xD;
          -  Autologous stem cell transplant within the last 6 weeks, or any allogeneic stem cell&#xD;
             transplant&#xD;
&#xD;
          -  Prior treatment with anti-BCMA therapy, any gene therapy, any genetically modified&#xD;
             cell therapy, or adoptive T cell therapy&#xD;
&#xD;
          -  History of HIV infection or acute or chronic active hepatitis B or C infection&#xD;
&#xD;
          -  Patients unwilling to participate in an extended safety monitoring period&#xD;
&#xD;
        Additional Exclusion Criteria for Nirogacestat plus ALLO-715 Cohorts&#xD;
&#xD;
          -  Inability to swallow tablets&#xD;
&#xD;
          -  Subject has known malabsorption syndrome or preexisting gastrointestinal conditions&#xD;
             that may impair absorption of nirogacestat&#xD;
&#xD;
          -  Use of strong/moderate CYP3A4 inhibitors, and strong CYP3A4 inducers within 14 days&#xD;
             before starting nirogacestat.&#xD;
&#xD;
          -  Use of concomitant medications that are known to prolong the QT/QTcF interval&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon/Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. David's South Austin Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 16, 2019</study_first_submitted>
  <study_first_submitted_qc>September 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2019</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

